Search Results - "Ary Harryanto Reksodiputro"

Chronic Myeloid Leukemia (CML) at National Referral Hospital in Indonesia by Wulyo Rajabto, Ary Harryanto Reksodiputro, Ikhwan Rinaldi, Hilman Tadjoedin, Dimas Priantono, Yohana Kusuma Angkasa

“…Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome and BCR-ABL fusion oncogene. CML…”
Get full text

Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate by Ikhwan Rinaldi, Ary Harryanto Reksodiputro

“…Introduction. The complete hematologic response is an integral part to achieve the complete cytogenetic response target and the major molecular response of…”
Get full text

Kesintasan Lima Tahun Pasien Mieloma Multipel Aktif berdasarkan Kriteria Diagnostik Durie-Salmon dan International Myeloma Working Group 2003 by Kurniawati, Sri Agustini, Reksodiputro, Ary Harryanto, Atmakusuma, Tubagus Djumhana

Get full text

Five Year Survival of Active Multiple Myeloma Patients Based on Durie-Salmon and International Myeloma Working Group 2003 Diagnostic Criteria by Sri Agustini Kurniawati, Ary Harryanto Reksodiputro, Tubagus Djumhana Atmakusuma

“…Introduction. Survival of active multiple myeloma (MM) patients is determined by early diagnosis and various prognostic factors. The development of MM…”
Get full text

Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) by Do, Young Rok, Kwak, Jae‐Yong, Kim, Jeong A., Kim, Hyeoung Joon, Chung, Joo Seop, Shin, Ho‐Jin, Kim, Sung‐Hyun, Bunworasate, Udomsak, Choi, Chul Won, Zang, Dae Young, Oh, Suk Joong, Jootar, Saengsuree, Reksodiputro, Ary Harryanto, Lee, Won Sik, Mun, Yeung‐Chul, Kong, Jee Hyun, Caguioa, Priscilla B., Kim, Hawk, Park, Jinny, Kim, Dong‐Wook

“…Summary In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher…”
Get full text

Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role by Rinaldi, Ikhwan, Reksodiputro, Ary Harryanto, Jusman, Sri Widia, Harahap, Alida, Setiabudy, Rianto, Wanandi, Septelia Inawati, Tambunan, Karmel, Suharti, Catharina

“…This study aimed to identify the association between duration of HU administration prior to IM treatment and MMR achievement in chronic-phase CML while…”
Get full text

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up by Do, Young Rok, Kwak, Jae-Yong, Kim, Hawk, Kim, Jeong-A, Kim, Hyeoung-Joon, Park, Joon Seong, Chung, Jooseop, Shin, Ho-Jin, Kim, Sung-Hyun, Bunworasate, Udomsak, Choi, Chul Won, Comia, Narcisa Sonia Cornejo, Zang, Dae Young, Oh, Sukjoong, Jootar, Saengsuree, Reksodiputro, Ary Harryanto, Lee, Won-Sik, Mun, Yeung-Chul, Kong, Jee Hyun, Caguioa, Priscilla B., Park, Jinny, Jung, Chul W., Kim, Dong-Wook

“…Background: In RERISE phase 3 study, radotinib demonstrated significantly higher and faster rates of major molecular response (MMR) than imatinib in patients…”
Get full text

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up by Do, Young Rok, Kim, Hawk, Kwak, Jae-Yong, Kim, Jeong-A, Kim, Hyeoung-Joon, Park, Joon Seong, Chung, Jooseop, Shin, Ho-Jin, Kim, Sung-Hyun, Bunworasate, Udomsak, Choi, Chul Won, Comia, Narcisa Sonia Cornejo, Zang, Dae Young, Oh, Sukjoong, Jootar, Saengsuree, Reksodiputro, Ary Harryanto, Lee, Won-Sik, Mun, Yeung-Chul, Kong, Jee Hyun, Caguioa, Priscilla B., Park, Jinny, Jung, Chul W., Kim, Dong-Wook

“…Background In RERISE phase 3 study, radotinib demonstrated significantly higher and faster rates of major molecular response (MMR) than imatinib in patients…”
Get full text

Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib by Lee, Sung-Eun, Choi, Soo Young, Kwak, Jae-Yong, Kim, Hawk, Kim, Jeong-A, Do, Young Rok, Kim, Hyeoung Joon, Park, Joon Seong, Chung, Joo Seop, Shin, Ho-Jin, Kim, Sung-Hyun, Kim, Dae-Young, Bunworasate, Udomsak, Choi, Chul Won, Comia, Narcisa Sonia Cornejo, Zang, Dae Young, Oh, Sukjoong, Jootar, Saengsuree, Reksodiputro, Ary Harryanto, Lee, Won Sik, Mun, Yeung-Chul, Kong, Jee Hyun, Caguioa, Priscilla B., Park, Jinny, Jung, Chul Won, Kim, Dong-Wook

“…Background: Recent studies have demonstrated that early molecular milestones were able to identify high-risk chronic myeloid leukemia patients treated with…”
Get full text

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial by Kwak, Jae-Yong, Kim, Hawk, Kim, Jeong A, Do, Young Rok, Kim, Hyeoung Joon, Park, Joon Seong, Chung, Joo Seop, Shin, Ho-Jin, Kim, Sung-Hyun, Kim, Dae-Young, Bunworasate, Udomsak, Choi, Chul Won, Comia, Narcisa Sonia Cornejo, Zang, Dae Young, Oh, Sukjoong, Jootar, Saengsuree, Reksodiputro, Ary Harryanto, Lee, Won Sik, Mun, Yeung-Chul, Kong, Jee Hyun, Caguioa, Priscilla B., Park, Jinny, Jung, Chul Won, Kim, Dong-Wook

“…▪ Background Radotinib is a second generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by IL-YANG Pharm. Co., Ltd (Seoul, South Korea) and approved…”
Get full text

Efficacy and Safety of New Product of Recombinant Erythropoietin to Treat Cisplatin-Containing Regimens-Induced Moderate Anemia in Cancer Patients by Atmakusuma, Tubagus Djumhana, Reksodiputro, Ary Harryanto, Kurnianda, Johan M

“…Background: Exogenous erythropoietin (EPO) is used widespread to treat patients with chemotherapy-induced anemia. Most of EPO products available in market are…”
Get full text

Infectious Complications in Asian Patients Treated with Alemtuzumab: Results From a Multicenter Study by Kim, Seok Jin, Reksodiputro, Ary Harryanto, Cheng, Ann-Lii, Intragumtornchai, Tanin, Issaragrisil, Surapol, Moon, Joon Ho, Kim, Jin Seok, Lee, Je-Jung, Won, Jong Ho, Kim, Won Seog, Kwong, Yok Lam

“…Abstract 5009 Alemtuzumab is a monoclonal humanized antibody reactive with CD52 antigen expressed in indolent B-cell non-Hodgkin lymphomas and variably…”
Get full text